Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 3
1984 4
1985 1
1987 1
1988 7
1991 1
1994 2
1996 1
1997 3
1998 3
1999 5
2000 5
2001 5
2002 6
2003 9
2004 13
2005 16
2006 17
2007 14
2008 17
2009 18
2010 18
2011 14
2012 14
2013 18
2014 20
2015 19
2016 20
2017 19
2018 17
2019 4
2020 9
2021 14
2022 10
2023 15
2024 5
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Results by year

Filters applied: . Clear all
Page 1
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Lu T, Hamidi H, Socinski MA, Reck M, Cappuzzo F, Barlesi F, Jotte RM, Müller S, Qamra A, Amitai A, Guan X, Fuentes E, Koeppen H, Giltnane JM, Shames DS, Ballinger M, He MX, Wang Y, Srivastava MK, Nabet BY. Lu T, et al. Among authors: socinski ma. Nat Commun. 2025 Dec 3. doi: 10.1038/s41467-025-66803-8. Online ahead of print. Nat Commun. 2025. PMID: 41339316 Free article.
In Reply.
Penault-Llorca F, Socinski MA. Penault-Llorca F, et al. Among authors: socinski ma. Oncologist. 2025 Sep 1;30(9):oyaf227. doi: 10.1093/oncolo/oyaf227. Oncologist. 2025. PMID: 40966469 Free PMC article. No abstract available.
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Meric-Bernstam F, Gutierrez M, Sanz-Garcia E, Villa D, Zhang J, Friedmann J, Yan F, Socinski MA, Sarantopoulos J, Raez LE, Chu QS, Chénard-Poirier M, Chatterjee MS, Ren H, Liu Q, Levine DA, Jhaveri KL. Meric-Bernstam F, et al. Among authors: socinski ma. Cancer Res Commun. 2025 Sep 1;5(9):1664-1673. doi: 10.1158/2767-9764.CRC-25-0019. Cancer Res Commun. 2025. PMID: 40762544 Free PMC article. Clinical Trial.
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.
Herbst RS, Prizant H, Ruderman D, Conway J, Shamshoian J, Koeppen H, Zou W, de Marinis F, Giaccone G, Jassem J, Spigel DR, Socinski MA, Reck M, Molinero L, Ballinger M, Shames D, Griffin M, Yu L, Agrawal N, Beck A, Wapinski I, Hennek S, Giltnane J, Srivastava MK. Herbst RS, et al. Among authors: socinski ma. J Thorac Oncol. 2025 Dec;20(12):1778-1790. doi: 10.1016/j.jtho.2025.07.131. Epub 2025 Aug 5. J Thorac Oncol. 2025. PMID: 40759194
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.
Zhang Y, Laine AM, Iyengar P, Westover KD, Dowell JE, Hughes RS, Christie A, Mickel T, Attia A, Villaruz L, Chen Y, Spigel DR, Socinski MA, Timmerman RD, Gerber DE. Zhang Y, et al. Among authors: socinski ma. Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):374-382. doi: 10.1016/j.ijrobp.2025.01.027. Epub 2025 Feb 6. Int J Radiat Oncol Biol Phys. 2025. PMID: 39922319 Clinical Trial.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Fortman D, Wang H, VanderWeele R, Evans T, Herman JG, Rhee J, Reyes V, McLaughlin B, Wozniak A, Somasundaram A, Mekhail T, Socinski MA, Schulze K, Villaruz LC. Fortman D, et al. Among authors: socinski ma. Clin Lung Cancer. 2025 Jan;26(1):78-81. doi: 10.1016/j.cllc.2024.10.014. Epub 2024 Oct 30. Clin Lung Cancer. 2025. PMID: 39578170 Free article.
Correlation of safety and efficacy of atezolizumab therapy across indications.
Durán-Pacheco G, Chandler GS, Maiya V, Socinski MA, Sonpavde G, Puente J, Essioux L, Carter C, Cardona JV, Mohindra R, Naidoo J. Durán-Pacheco G, et al. Among authors: socinski ma. J Immunother Cancer. 2024 Nov 12;12(11):e010158. doi: 10.1136/jitc-2024-010158. J Immunother Cancer. 2024. PMID: 39537212 Free PMC article.
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW. Rodon J, et al. Among authors: socinski ma. ESMO Open. 2024 Apr;9(4):102961. doi: 10.1016/j.esmoop.2024.102961. Epub 2024 Apr 18. ESMO Open. 2024. PMID: 38640748 Free PMC article. Clinical Trial.
338 results